<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003363</url>
  </required_header>
  <id_info>
    <org_study_id>18/NE/0289</org_study_id>
    <nct_id>NCT04003363</nct_id>
  </id_info>
  <brief_title>The United Kingdom National Registry for Myotonic Dystrophy</brief_title>
  <official_title>The UK National Registry for Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newcastle University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myotonic dystrophy (dystrophia myotonica - DM) exists in two forms, usually referred to as
      DM1 (type 1) and DM2 (type 2). Both conditions are genetic disorders but each affects a
      different gene. DM1 is the most common adult-onset muscular dystrophy, and is thought to
      affect at least 1 in 8,000 people worldwide.

      The aim is to facilitate a questionnaire based research study in order to better characterise
      and understand the disease in the UK. By maintaining a national registry this will help
      identify potential participants eligible for clinical trials in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The UK DM Patient Registry (https://www.dm-registry.org/uk/) aims to recruit any individual,
      from anywhere within the United Kingdom, with a diagnosis of myotonic dystrophy who may be
      interested in becoming involved in future planned clinical trials. Participants may be
      referred to the registry by health care professionals, genetic testing/laboratory centres who
      are aware of the registry. Alternatively, a participant may have discovered the registry via
      promotional activities or by their own online searches. After completing the consent process,
      participants are able to enter information on to the registry platform (note all forms are
      also available offline as well). This is an ongoing database and all participants will
      invited to update their information on an annual basis.

      The registry is sponsored by Muscular Dystrophy UK and the Myotonic Dystrophy Support Group.

      The database is divided into two main sections:

        1. Mandatory items (demographic information, clinical diagnosis, genetic test result,
           current best motor function and wheelchair use) and

        2. Highly encouraged items (severity of muscle symptoms, cardiac status, respiratory
           function, digestion, cataracts, and fatigue, ethnic origin and data on involvement with
           other registries)

      The database is designed to be self reporting, however where specialised clinical or genetic
      information is required, the neuromuscular specialist in charge of the participants care can
      be invited to provide some additional information. The participant is able to select a health
      care provider from a pre-populated list at registration stage, if they wish to (optional
      feature). This information is included in the patient information and consent. Relevant R&amp;D
      approval has been sought.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Years</target_duration>
  <primary_outcome>
    <measure>Patient questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported myotonic dystrophy clinical diagnosis, symptoms relating to muscle weakness, motor function, medication use, family history and ethnicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Clinician reported patient cardiac measures, medication use, respiratory measures and genetic confirmation of myotonic dystrophy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Myotonic Dystrophy</condition>
  <arm_group>
    <arm_group_label>Participants with Myotonic Dystrophy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Registry</intervention_name>
    <description>Participants who have volunteered to participate will complete various questionnaires relating to their condition.</description>
    <arm_group_label>Participants with Myotonic Dystrophy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Myotonic Dystrophy will volunteer to participate in this study. The study
        will be advertised through neuromuscular disease clinics, the registry website, patient
        organisations and conferences and meetings throughout the UK.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with a confirmed Myotonic Dystrophy diagnosis (or pending diagnosis) are
             eligible for inclusion. Diagnosis will be confirmed via genetic testing results

        Exclusion Criteria:

          -  There are no exclusion criteria for the registry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiara Marini-Bettolo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Walton Muscular Dystrophy Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Registry Project Manager and Curator</last_name>
    <phone>0191 2418640</phone>
    <email>ben.porter@newcastle.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Walton Muscular Dystrophy Research Centre</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Registry Project Manager and Curator</last_name>
      <phone>0191 2418640</phone>
      <email>ben.porter@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Chiara Marini-Bettolo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Wood L, Cordts I, Atalaia A, Marini-Bettolo C, Maddison P, Phillips M, Roberts M, Rogers M, Hammans S, Straub V, Petty R, Orrell R, Monckton DG, Nikolenko N, Jimenez-Moreno AC, Thompson R, Hilton-Jones D, Turner C, Lochm端ller H. The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. J Neurol. 2017 May;264(5):979-988. doi: 10.1007/s00415-017-8483-2. Epub 2017 Apr 10.</citation>
    <PMID>28397002</PMID>
  </results_reference>
  <results_reference>
    <citation>Best AF, Hilbert JE, Wood L, Martens WB, Nikolenko N, Marini-Bettolo C, Lochm端ller H, Rosenberg PS, Moxley RT 3rd, Greene MH, Gadalla SM. Survival patterns and cancer determinants in families with myotonic dystrophy type 1. Eur J Neurol. 2019 Jan;26(1):58-65. doi: 10.1111/ene.13763. Epub 2018 Sep 16.</citation>
    <PMID>30051542</PMID>
  </results_reference>
  <results_reference>
    <citation>Alsaggaf R, Wang Y, Marini-Bettolo C, Wood L, Nikolenko N, Lochm端ller H, Greene MH, Gadalla SM. Benign and malignant tumors in the UK myotonic dystrophy patient registry. Muscle Nerve. 2018 Feb;57(2):316-320. doi: 10.1002/mus.25736. Epub 2017 Jul 24.</citation>
    <PMID>28662292</PMID>
  </results_reference>
  <results_reference>
    <citation>Wood L, Bassez G, Bleyenheuft C, Campbell C, Cossette L, Jimenez-Moreno AC, Dai Y, Dawkins H, Manera JAD, Dogan C, El Sherif R, Fossati B, Graham C, Hilbert J, Kastreva K, Kimura E, Korngut L, Kostera-Pruszczyk A, Lindberg C, Lindvall B, Luebbe E, Lusakowska A, Mazanec R, Meola G, Orlando L, Takahashi MP, Peric S, Puymirat J, Rakocevic-Stojanovic V, Rodrigues M, Roxburgh R, Schoser B, Segovia S, Shatillo A, Thiele S, Tournev I, van Engelen B, Vohanka S, Lochm端ller H. Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet J Rare Dis. 2018 Sep 5;13(1):155. doi: 10.1186/s13023-018-0889-0. Erratum in: Orphanet J Rare Dis. 2019 Aug 15;14(1):199.</citation>
    <PMID>30185236</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myotonic Dystrophy</keyword>
  <keyword>Myotonic Dystrophy Type 1</keyword>
  <keyword>Myotonic Dystrophy Type 2</keyword>
  <keyword>DM</keyword>
  <keyword>DM1</keyword>
  <keyword>DM2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

